Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cassava Sciences ( (SAVA) ) has issued an announcement.
On August 4, 2025, Cassava Sciences announced positive preclinical results from a study evaluating simufilam in a mouse model of TSC-related epilepsy. Conducted in collaboration with the TSC Alliance and PsychoGenics, Inc., the study demonstrated that simufilam attenuated seizure progression with a significant dose-response relationship. These findings support simufilam’s potential as a novel treatment for TSC-related epilepsy, with a clinical study expected to begin in the first half of 2026.
The most recent analyst rating on (SAVA) stock is a Buy with a $116.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing novel treatments for central nervous system disorders, including tuberous sclerosis complex (TSC)-related epilepsy. The company’s investigational treatments include simufilam, a proprietary oral small molecule believed to modulate the activity of the filamin A protein.
Average Trading Volume: 1,058,675
Technical Sentiment Signal: Sell
Current Market Cap: $102.4M
For a thorough assessment of SAVA stock, go to TipRanks’ Stock Analysis page.